Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)

Market Cap	41.27B +846.2%
Revenue (ttm)	1.53B +40.6%
Net Income	192.74M +416.4%
EPS	0.48 +410.2%
Shares Out	436.90M
PE Ratio	122.15
Forward PE	70.66
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,861,500
Average Volume	1,393,242
Open	54.00
Previous Close	53.80
Day's Range	54.00 - 60.80
52-Week Range	11.10 - 63.85
Beta	0.32
RSI	59.63
Earnings Date	Mar 26, 2026

About HKG:2315

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally. It operates through five segments: Gene-editing services, Pre-clinical pharmacology and efficacy evaluation, Animal models selling, Antibody development, and Innovative drugs development. The Gene-editing services segment provides the customized gene editing services based on animals as well as c...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 1,306
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2315

Financial Performance

In 2025, HKG:2315's revenue was 1.38 billion, an increase of 40.63% compared to the previous year's 980.45 million. Earnings were 173.20 million, an increase of 416.37%.

Financial numbers in CNY